Schedule 13D ownership disclosure

TriSalus Life Sciences Inc

Common Stock, $0.0001 par value · CUSIP: 89680M101

Event date: 2024-12-17

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Frankenius Equity ABReported CIK 0001988262

    Shares: 6,488,719.00 · Class: 20.9%

  • Paul Frankenius

    Shares: 6,488,719.00 · Class: 20.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001415889-24-029845
Form type
SCHEDULE 13D/A
Filer
Frankenius Equity AB
CIK
CIK 1988262
Filed
Dec 19, 2024
Reporting period
Dec 17, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub